STAT

HHS nominee Azar signals new line of attack on drug prices

Lawmakers are grilling Azar about his plans to bring down drug prices and his role in pricing decisions in his last job.
Alex Azar testifies during a Senate Finance Committee hearing on Tuesday. Source: Carolyn Kaster/AP

WASHINGTON — Alex Azar, Trump’s pick to lead the Health and Human Services Department, doubled down on his commitment to bringing down prescription drug prices Tuesday — and even added a new target for future policymaking: drug makers’ list prices.

Lawmakers at Azar’s confirmation hearing Tuesday before the Senate Finance Committee, like those at an earlier hearing before a separate panel, grilled him repeatedly about his plans, as president of Eli Lilly’s U.S. business.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
Opinion: In A Medical Emergency, Who In Your Social Network Will Call For Help Quickest?
Applying the "strength of weak ties" theory to medicine, a weakly connected familiar in your social network can be the outside voice of reason who isn't afraid to call for…
STAT3 min read
Why Are Elite Athletes Different Than The Rest Of Us? Take A Look At Their Microbes
Elite athletes really are different from you and me. Or, at least their gut microbes are. Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particu
STAT2 min read
AbbVie To Acquire Allergan For $63 Billion In Megamerger Of Pharma Giants
AbbVie said Tuesday it will acquire Allergan for $63 billion — the latest megamerger between two pharma giants seeking new ways to grow.